74048-23-0

Basic information

• Product Name: 3,4-diphenyl-5-ethylisoxazole
• Synonyms: 3,4-diphenyl-5-ethylisoxazole
• CAS NO: 74048-23-0
• Molecular Weight: 249.312
• Mol File: 74048-23-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 3,4-diphenyl-5-ethylisoxazole(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-diphenyl-5-ethylisoxazole(74048-23-0)
• EPA Substance Registry System: 3,4-diphenyl-5-ethylisoxazole(74048-23-0)

Safety Data

• Hazardous Substances Data: 74048-23-0(Hazardous Substances Data)

Upstream product

• 91711-66-9 (E)-1,2-diphenylpent-1-en-3-one 
• 181696-73-1 3,4-diphenyl-4-hydrido-5-hydroxy-5-methylisoxazole 
• 37928-17-9 5-methyl-3,4-diphenyl isoxazole 
• 74-88-4 methyl iodide 
• 74048-21-8 1-nitro-1,2-diphenyl-1-pentene-3-one 

Relevant articles and documents

Functionalized diarylisoxazoles inhibitors of ciclooxygenase

The present invention refers to isoxazole derivatives, in particular diarylisoxazole derivatives inhibitors of cyclooxygenase (COX), in particular cyclooxygenase-1 (COX-1), to their pharmaceutical compositions, the process for their preparation and their use for the chemoprevention and treatment of inflammatory syndromes and in the prevention and treatment of carcinomas, in particular intestinal, ovarian and cutaneous carcinomas, in the treatment of pain syndromes, in particular after surgery, and in the cardiovascular field as antithrombotics/vasoprotectives/cardioprotectives.

Novel synthesis of 3,4-diarylisoxazole analogues of valdecoxib: Reversal cyclooxygenase-2 selectivity by sulfonamide group removal

3,4-Diarylisoxazole analogues of valdecoxib [4-(5-methyl-3-phenylisoxazol- 4-yl)-benzensulfonamide], a selective cyclooxygenase-2 (COX-2) inhibitor, were synthesized by 1,3-dipolar cycloaddition of arylnitrile oxides to the enolate ion of phenylacetone regioselectively prepared in situ with lithium diisopropylamide at 0 °C. The corresponding 3-aryl-5-methyl-4-phenyl- isoxazoles were easily generated by a dehydration/aromatization reaction under basic conditions of 3-aryl-5-hydroxy-5-methyl-4-phenyl-2-isoxazolines and further transformed into their benzenesulfonamide derivatives. The biochemical COX-1/COX-2 selectivity was evaluated in vitro by using the human whole blood assays of COX isozyme activity. Three compounds not bearing the sulfonamide group present in valdecoxib were selective COX-1 inhibitors.